Brightgene Bio-Medical Technology688166.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Brightgene Bio-Medical Technology (688166.SH) trades at a P/E of 140.00x, P/B of 4.42x, P/S of 9.93x, and a dividend yield of 0.05%.
Longitudinal percentile comparison: P/E sits at the 67th percentile over the trailing 10Y window (vs. 49th percentile over 3Y); P/B sits at the 8th percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 28th percentile over the trailing 10Y window (vs. 20th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 87th percentile within its industry and the 86th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.13%, ranking at the 18th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 58.3 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Brightgene Bio-Medical Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688166 · SSE: 688166 · 688166
Want the full picture on whether Brightgene Bio-Medical Technology (688166.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 140.00 | ||||||
| P/B (MRQ) | 4.42 | ||||||
| P/S (TTM) | 9.93 | ||||||
| Dividend Yield | 0.05% | ||||||
| Buyback + Div Yield | 0.13% |